Compare PSNYW & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNYW | ALXO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Sweden | United States |
| Employees | 2547 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.5M | 240.8M |
| IPO Year | N/A | 2020 |
| Metric | PSNYW | ALXO |
|---|---|---|
| Price | $3.21 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 6.3K | ★ 1.0M |
| Earning Date | 03-06-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,034,261,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.49 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.41 |
| 52 Week High | $7.50 | $2.66 |
| Indicator | PSNYW | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 59.42 |
| Support Level | $2.88 | $1.99 |
| Resistance Level | $3.99 | $2.30 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 28.44 | 89.52 |
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.